Novo Nordisk A/S $NVO Stake Boosted by Mayflower Financial Advisors LLC

Mayflower Financial Advisors LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 46.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,454 shares of the company’s stock after purchasing an additional 2,380 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $514,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of NVO. Kingstone Capital Partners Texas LLC increased its stake in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after purchasing an additional 10,001,898 shares in the last quarter. Nuveen LLC purchased a new position in Novo Nordisk A/S in the 1st quarter worth about $370,272,000. Amundi increased its stake in Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after purchasing an additional 1,627,051 shares in the last quarter. Acadian Asset Management LLC increased its stake in Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after purchasing an additional 1,038,137 shares in the last quarter. Finally, Folketrygdfondet increased its stake in Novo Nordisk A/S by 6.9% in the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock worth $661,202,000 after purchasing an additional 617,974 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. HSBC set a $70.00 price target on Novo Nordisk A/S in a research note on Wednesday, October 1st. TD Cowen lowered their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $76.00.

Novo Nordisk A/S Trading Down 1.3%

NYSE:NVO opened at $51.36 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $113.76. The stock’s 50-day moving average is $56.43 and its two-hundred day moving average is $62.14. The stock has a market cap of $229.30 billion, a PE ratio of 14.11, a price-to-earnings-growth ratio of 2.37 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.